PetVivo Holdings, Inc. Achieves National Distribution of Spryng™ to More than 600 Veterinary Clinics in 49 States
MINNEAPOLIS, MN, US, Dec. 11, 2023 (GLOBE NEWSWIRE) — PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) (the “Company”), an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for companion animals, achieved a significant milestone – the sale of its signature product Spryng™ with OsteoCushion™ Technology to more than 600 veterinary clinics in 49 states.
“We are incredibly excited about the acceptance by veterinarians of our life changing product, Spryng with OsteoCushion Technology, which has been distributed to more than 600 clinics in 49 states,” said John Lai, Chief Executive Officer of PetVivo Holdings, Inc. “The rapid increase in the number of clinics purchasing Spryng demonstrates an advancement in awareness of Spryng throughout the veterinary community. This advance was demonstrated by the increase of veterinarian inquiries and podium speaker references related to Spryng at the American Association of Equine Practitioners (“AAEP”) conference over the past three years. When we first launched Spryng at the AAEP conference in Nashville three years ago no one knew about the product; last year in San Antonio veterinarians were informing us that they had heard of Spryng, but were unaware of veterinarians using the product; a few weeks ago at the AAEP conference in San Diego veterinarians were sharing with us that they knew veterinarians using the product and experiencing beneficial results. Such awareness gives us confidence that veterinarians are reaching for Spryng as a viable option for the management of lameness and joint related afflictions, such as osteoarthritis.”
SPRYNG™ with OsteoCushion™ Technology, is an intra-articular injectable veterinary medical device consisting of sterilized, extra-cellular matrix microparticles. The microparticles of Spryng have been found to adsorb onto the joint synovial lining of animals and subsequently integrate with the animal’s subsynovial tissue. Such action promotes the restoration of proper joint mechanics, thereby aiding in the management of lameness and other joint-related afflictions, such as osteoarthritis.
“We are also seeing enthusiasm surrounding Spryng in the veterinary community with veterinarians sending us videos and images touting the benefits of Spryng,” said Mr. Lai. “For example, Dr. Tomas Infernuso recently provided a video demonstrating the injection of Spryng in the contralateral knee of a dog following a TPLO procedure.”
To view an injection of Spryng performed by Dr. Infernuso please visit:
https://youtube.com/shorts/OqodTbf01i0?feature=share.
For more information about PetVivo Holdings, Inc. and its innovative product, Spryng, please contact info1@petvivo.com or visit https://petvivo.com/ and https://sprynghealth.com/.
About PetVivo Holdings, Inc.
PetVivo Holdings Inc. (NASDAQ: PETV & PETVW) is an emerging biomedical device company currently focused on the manufacturing, commercialization and licensing of innovative medical devices and therapeutics for companion animals. The Company’s strategy is to leverage human therapies for the treatment of companion animals in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than more stringently regulated pharmaceuticals and biologics.
PetVivo has a pipeline of seventeen products for the treatment of animals and people. A portfolio of twenty patents protects the Company’s biomaterials, products, production processes and methods of use. The Company’s lead product SPRYNG, a veterinarian-administered, intraarticular injection for the treatment of lameness and other joint-related afflictions, including osteoarthritis, in dogs and horses, is currently available for commercial sale to veterinarians.
CONTACT:
John Lai, CEO
PetVivo Holdings, Inc.
Email: info1@petvivo.com
(952) 405-6216
Forward-Looking commercial Statements:
The foregoing material may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation the Company’s proposed development and commercial timelines, and can be identified by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available the Company and its current plans or expectations and are subject to a number of uncertainties and risks that could significantly affect current plans. Risks concerning the Company’s business are described in detail in the Company’s Annual Report on Form 10-K for the year ended March 31, 2023 and other periodic and current reports filed with the Securities and Exchange Commission. The Company is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
